Extremely preterm infants and risk of developing neurodevelopmental impairment later in childhood

A meta-analysis of previously reported studies by Gregory P. Moore, M.D., F.R.C.P.C., of The Ottawa Hospital, Ontario, Canada, and colleagues examined the rate of moderate to severe and severe neurodevelopmental impairment by gestational age in extremely preterm survivors followed up between ages 4 and 8 years, and determined whether there is a significant difference in impairment rates between the successive weeks of gestation of survivors.

The search of English-language publications found nine studies that met inclusion criteria of being published after 2004, a , follow-up rate of 65 percent or more, use of or classification for impairment, reporting by gestation, and meeting prespecified definitions of impairment. Researchers then extracted data using a structured data collection form and investigators were contacted for data clarification.

According to the study results, all extremely preterm infant survivors have a substantial likelihood of developing moderate to severe impairment. Wide confidence intervals at the lower gestations (eg. at 22 weeks, 43 percent) and high at the higher gestations (eg. at 25 weeks, 24 percent) limit the results. There was a statistically significant absolute decrease in moderate to severe impairment between each week of gestation.

"Knowledge of these data, including the limitations, should facilitate discussion during the shared decision-making process about care plans for these infants, particularly in centers without their own data," the study concludes.

More information: JAMA Pediatr. Published online August 26, 2013. DOI: 10.1001/jamapediatrics.2013.2395

Related Stories

Etanercept reduces work, activity impairment in RA

date Jul 01, 2013

(HealthDay)—For patients with moderate-to-severe rheumatoid arthritis (RA), continued etanercept treatment is associated with reduced work and activity impairment, according to a study published online ...

Recommended for you

Antibiotic approved for treating infant abdominal infections

date 8 hours ago

The antibiotic meropenem was approved by the U. S. Food and Drug Administration for treating abdominal infections in children less than 3 months of age. The approval came after a study by a National Institutes of Health research ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.